ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1474

Automatic Detection of Bone Marrow Lesions from Knee MRI Data from the OAI Study

Shen Liu1, Xiaoxiao Sun1, Frank Roemer2, Erin Ashbeck3, Edward Bedrick1, Zong-Ming Li1, Ali Guermazi4 and Kent Kwoh1, 1University of Arizona, Tucson, AZ, 2Friedrich-Alexander University Erlangen-Nurnberg, Erlangen, Germany, 3University of Arizona Arthritis Center, Tucson, AZ, 4Boston University, Boston, MA

Meeting: ACR Convergence 2021

Keywords: bone marrow lesions, Deep Learning, Imaging, Magnetic resonance imaging (MRI), OAI

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Title: Osteoarthritis & Joint Biology – Basic Science Poster (1468–1479)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Subchondral bone marrow lesions (BMLs) are associated with symptoms and structural progression of knee OA. BMLs are characterized by diffuse hyperintensity on fat suppressed T2-weighted images. BMLs are commonly assessed using semi-quantitative (SQ) scoring systems by expert readers or volume quantification. Automated detection of BMLs using machine learning approaches may help in screening potential participants in clinical trials enriched for fast structural progression.

Methods: The dataset consists of 1,899 knee MRI exams from three sub-studies of the Osteoarthritis Initiative (OAI) with available baseline SQ readings: Foundation for NIH (FNIH) OA biomarker, Pivotal OAI MRI Analysis (POMA) incident radiographic knee OA, and POMA knee replacement. We trained a deep learning model (modified MRNet) using the sagittal intermediate-weighted (IW) fat-suppressed (FS) images. We dichotomized the MOAKS (MRI Osteoarthritis Knee Score) grades into presence or absence categories. The split was done by categorizing grades > 0 as presence and grades = 0 as absence. The whole data were randomly split into a training set (1524 exams) to train the model, a validation set (182 exams) to select the best model, and a test set (193 exams) to evaluate prediction performance. After the deep learning models were trained, we obtained probabilities of the existence of BMLs from IW images on each of 15 subregions in the femur and tibia. The logistic regression model was trained to combine the probabilities of different regions for IW images to output a probability of BMLs status for each subject overall. We utilized the area under the receiver operating characteristic curve (AUC) to assess the model’s performance and 95% confidence intervals of AUC to measure the variability of AUC. AUC values range from 0 to 1, with 1 indicating a 100% correct detection.

Results: The highest AUC value for IW images in the test set was 0.90 at two regions (tibia central medial and patella lateral). AUC values ranged from 0.51 to 0.89 in the test set for the other regions, see Table 1. At the subject level, the detection performance of the combined model achieved an AUC value of 0.87 with a 95% confidence interval of [0.82, 0.93].

Conclusion: We have developed and validated a fully automated deep learning framework to detect BMLs from MRI data. After the model had been trained, we applied the trained model to MRI data without MOAKS readings to predict the probability of BMLs status automatically. The prediction performance of detecting BMLs varied among different regions. Our method has some limitations, e.g., the prediction accuracy at the subject level is not as good as the accuracy for the individual subregions. In future studies, we will utilize images from other MRI sequences and additional MOAKS readings to improve our model’s performance. Automated classification of diffuse vs cystic BMLs and severity grading will be important in addition.

Table 1. AUC values for the test set.


Disclosures: S. Liu, None; X. Sun, None; F. Roemer, None; E. Ashbeck, EMD Serono, 2; E. Bedrick, None; Z. Li, None; A. Guermazi, Pfizer, MerckSerono, Regeneron, TissueGene, AstraZeneca, Novartis, 2, BICL, 8; K. Kwoh, Regeneron, 2, LG Chem, 2, Express Scripts, 2, Abbvie, 12, Principal investigator for pharma sponsored clinical trials, UCB, 12, Principal investigator for pharma sponsored clinical trials, Eicos, 12, Principal investigator for pharma sponsored clinical trials, Cumberland, 12, Principal investigator for pharma sponsored clinical trials, Mitsubishi, 12, Principal investigator for pharma sponsored clinical trials, GSK, 12, Principal investigator for pharma sponsored clinical trials, Kolon TissueGene, 4, Avalor Therapeutics, 4.

To cite this abstract in AMA style:

Liu S, Sun X, Roemer F, Ashbeck E, Bedrick E, Li Z, Guermazi A, Kwoh K. Automatic Detection of Bone Marrow Lesions from Knee MRI Data from the OAI Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/automatic-detection-of-bone-marrow-lesions-from-knee-mri-data-from-the-oai-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/automatic-detection-of-bone-marrow-lesions-from-knee-mri-data-from-the-oai-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology